Lewis Karen has filed 31 insider transactions across 1 company since April 2022.
Most recent transaction: a sale of 364 shares of Apellis Pharmaceuticals, Inc. ($APLS) on January 29, 2025.
Activity breakdown: 0 open-market purchases and 15 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 364 | $29.52 | 70,251.0000 | 123,905,000 | 0.52% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 1751 | $30.43 | 70,615.0000 | 123,905,000 | 2.42% | 0.00% |
| Jan. 17, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 1241 | $29.96 | 43,858.0000 | 123,905,000 | 2.75% | 0.00% |
| Jan. 21, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Common Stock | 28508 | $0.00 | 72,366.0000 | 123,905,000 | 65.00% | 0.02% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 1599 | $28.70 | 45,099.0000 | 123,905,000 | 3.42% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 367 | $64.14 | 47,270.0000 | 118,678,000 | 0.77% | 0.00% |
| Jan. 30, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 883 | $65.53 | 46,387.0000 | 118,678,000 | 1.87% | 0.00% |
| Jan. 23, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 4286 | $63.69 | 47,637.0000 | 118,678,000 | 8.25% | 0.00% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 1738 | $65.00 | 51,923.0000 | 118,678,000 | 3.24% | 0.00% |
| Jan. 17, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 3276 | $65.58 | 53,661.0000 | 118,678,000 | 5.75% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Common Stock | 16963 | $0.00 | 58,569.0000 | 118,678,000 | 40.77% | 0.01% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 1632 | $66.81 | 56,937.0000 | 118,678,000 | 2.79% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Stock Option (Right to Buy) | 24666 | $66.30 | 24,666.0000 | 118,678,000 | 9999.99% | 0.02% |
| June 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | M | Common Stock | 5000 | $34.11 | 46,504.0000 | 106,114,000 | 12.05% | 0.00% |
| June 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 5000 | $86.00 | 41,504.0000 | 106,114,000 | 10.75% | 0.00% |
| June 1, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 106,000.0000 | 106,114,000 | 4.50% | 0.00% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | M | Common Stock | 5000 | $34.11 | 46,430.0000 | 106,114,000 | 12.07% | 0.00% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 5000 | $75.00 | 41,430.0000 | 106,114,000 | 10.77% | 0.00% |
| April 3, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | M | Stock Option (Right to Buy) | 5000 | $0.00 | 111,000.0000 | 106,114,000 | 4.31% | 0.00% |
| Feb. 23, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 1104 | $68.76 | 41,430.0000 | 106,114,000 | 2.60% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Common Stock | 6628 | $0.00 | 43,087.0000 | 106,114,000 | 18.18% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | F | Common Stock | 553 | $58.50 | 42,534.0000 | 106,114,000 | 1.28% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Stock Option (Right to Buy) | 9402 | $0.00 | 9,402.0000 | 106,114,000 | 9999.99% | 0.01% |
| Jan. 30, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 883 | $52.76 | 36,459.0000 | 106,114,000 | 2.36% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | F | Common Stock | 367 | $52.77 | 37,342.0000 | 106,114,000 | 0.97% | 0.00% |
| Jan. 23, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | S | Common Stock | 2955 | $51.58 | 37,709.0000 | 106,114,000 | 7.27% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | F | Common Stock | 1411 | $52.05 | 40,664.0000 | 106,114,000 | 3.35% | 0.00% |
| April 25, 2022 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | J | Common Stock | 1250 | $0.00 | 22,224.0000 | 0 | 5.33% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Common Stock | 19634 | $0.00 | 42,075.0000 | 106,114,000 | 87.49% | 0.02% |
| April 25, 2022 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | J | Stock Option (Right to Buy) | 7500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Lewis Karen | Chief People Officer | A | Stock Option (Right to Buy) | 30845 | $52.66 | 30,845.0000 | 106,114,000 | 9999.99% | 0.03% |